View Future GrowthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsHeska 과거 순이익 실적과거 기준 점검 0/6Heska 의 수입은 연평균 -55.5%의 비율로 감소해 온 반면, Medical Equipment 산업은 연평균 15.3%의 비율로 증가했습니다. 매출은 연평균 19.4%의 비율로 증가해 왔습니다.핵심 정보-55.49%순이익 성장률-52.58%주당순이익(EPS) 성장률Medical Equipment 산업 성장률8.90%매출 성장률19.36%자기자본이익률-4.80%순이익률-7.86%최근 순이익 업데이트31 Mar 2023최근 과거 실적 업데이트Reported Earnings • May 06First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.97 loss per share (further deteriorated from US$0.97 loss in 1Q 2022). Revenue: US$62.4m (down 3.7% from 1Q 2022). Net loss: US$10.1m (loss widened 1.4% from 1Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Reported Earnings • Mar 01Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1,923 loss per share (further deteriorated from US$0.12 loss in FY 2021). Revenue: US$257.3m (up 1.4% from FY 2021). Net loss: US$19.9m (loss widened US$18.7m from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.공시 • Feb 09Heska Corporation to Report Q4, 2022 Results on Feb 28, 2023Heska Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 28, 2023Reported Earnings • Nov 09Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.042 loss per share (improved from US$0.19 loss in 3Q 2021). Revenue: US$61.5m (up 2.1% from 3Q 2021). Net loss: US$436.0k (loss narrowed 77% from 3Q 2021). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Reported Earnings • Aug 08Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.51 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$64.7m (flat on 2Q 2021). Net loss: US$5.25m (loss widened US$4.68m from 2Q 2021). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 374%. Over the next year, revenue is forecast to grow 16%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.97 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$64.8m (up 7.1% from 1Q 2021). Net loss: US$9.99m (down US$11.9m from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 471%. Over the next year, revenue is forecast to grow 15%, compared to a 9.0% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.모든 업데이트 보기Recent updates공시 • Jun 15Heska Corporation(NasdaqCM:HSKA) dropped from NASDAQ Composite IndexHeska Corporation removed공시 • Jun 14Heska Corporation Announces Board ChangesHeska Corporation announced that pursuant to the Merger Agreement, at the Effective Time, all of the members of the company's board of directors (which consisted of Sharon J. Maples, David E. Sveen, Ph.D., Stephen L. Davis, Robert L. Antin, Mark F. Furlong, Dr. Joachim Hasenmaier, Scott W. Humphrey and Kevin S. Wilson) ceased to be directors of the company, and Nefertiti Greene, Giamabatista Martano and Timothy Hirsch became directors of the company. Also in connection with the Merger and as contemplated by the Merger Agreement, following the consummation of the Merger, Nefertiti Greene, Giambatista Martano, Timothy Hirsch, Keith Melman, Anthony Gedeller, Peter Kim and Chad Susie became officers of the company.Reported Earnings • May 06First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.97 loss per share (further deteriorated from US$0.97 loss in 1Q 2022). Revenue: US$62.4m (down 3.7% from 1Q 2022). Net loss: US$10.1m (loss widened 1.4% from 1Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Price Target Changed • Apr 04Price target increased by 22% to US$130Up from US$106, the current price target is an average from 4 analysts. New target price is 11% above last closing price of US$117. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.92 last year.Reported Earnings • Mar 01Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1,923 loss per share (further deteriorated from US$0.12 loss in FY 2021). Revenue: US$257.3m (up 1.4% from FY 2021). Net loss: US$19.9m (loss widened US$18.7m from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.공시 • Feb 09Heska Corporation to Report Q4, 2022 Results on Feb 28, 2023Heska Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 28, 2023분석 기사 • Feb 09Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?Heska Corporation ( NASDAQ:HSKA ), is not the largest company out there, but it saw a significant share price rise of...공시 • Feb 02Heska Corporation Announces Nancy Wisnewski Step Downs as Executive Vice President and Chief Operating Officer, Effective March 31, 2023On January 27, 2023, Nancy Wisnewski, Ph.D., Executive Vice President, Chief Operating Officer of Heska Corporation (the “Company”), informed the Company that after more than 30 years of service, she will step down from such position effective March 31, 2023. Dr. Wisnewski will remain with the Company in the position of Chief Science Advisor to the CEO. The Company expects to prepare operational team leadership changes in advance of the transition that begins March 31, 2023.분석 기사 • Jan 18Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 50%?How far off is Heska Corporation ( NASDAQ:HSKA ) from its intrinsic value? Using the most recent financial data, we'll...공시 • Jan 04Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc.Heska Corporation (NasdaqCM:HSKA) entered a definitive agreement to acquire MBio Diagnostics, Inc. for $38.7 million on September 9, 2022. The consideration includes a mix of cash and debt forgiveness, subject to working capital and other adjustments. The transaction is expected to close in the first half of 2023, subject to customary closing conditions. As per the filling on November 8, 2022, both companies board of directors approved the merger. Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc. on January 3, 2023.Price Target Changed • Nov 16Price target decreased to US$123Down from US$142, the current price target is an average from 5 analysts. New target price is 73% above last closing price of US$70.92. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$0.11 last year.Reported Earnings • Nov 09Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.042 loss per share (improved from US$0.19 loss in 3Q 2021). Revenue: US$61.5m (up 2.1% from 3Q 2021). Net loss: US$436.0k (loss narrowed 77% from 3Q 2021). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Seeking Alpha • Sep 12Heska to acquire LightDeck Diagnostics for $38.7MHeska (NASDAQ:HSKA) to acquire 100% of the share capital of MBio Diagnostics, d/b/a LightDeck Diagnostics, an innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Heska will purchase LightDeck for a purchase price of $38.7 million. Transaction is expected to close in H1 2023.Recent Insider Transactions Derivative • Sep 07Executive VP & COO exercised options to buy US$880k worth of stock.On the 1st of September, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$8.55, costing a total of US$86k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2021, Nancy's direct individual holding has increased from 54.52k shares to 71.03k. Company insiders have collectively bought US$1.5m more than they sold, via options and on-market transactions, in the last 12 months.분석 기사 • Sep 07Is Heska (NASDAQ:HSKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Major Estimate Revision • Aug 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$1.31 to -US$1.45 per share. Revenue forecast unchanged at US$273.3m. Medical Equipment industry in the US expected to see average net income growth of 11% next year. Consensus price target broadly unchanged at US$147. Share price rose 5.4% to US$95.69 over the past week.분석 기사 • Aug 17Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 31%?How far off is Heska Corporation ( NASDAQ:HSKA ) from its intrinsic value? Using the most recent financial data, we'll...Reported Earnings • Aug 08Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.51 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$64.7m (flat on 2Q 2021). Net loss: US$5.25m (loss widened US$4.68m from 2Q 2021). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 374%. Over the next year, revenue is forecast to grow 16%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.Seeking Alpha • Aug 08Heska Non-GAAP EPS of $0.34 misses by $0.03, revenue of $64.7M misses by $3.76MHeska press release (NASDAQ:HSKA): Q2 Non-GAAP EPS of $0.34 misses by $0.03. Revenue of $64.7M (-0.4% Y/Y) misses by $3.76M. Consolidated gross margin improved approximately 30 bps to 42.3%. Consolidated operating margin declined from negative 1.1% to negative 8.6%.Major Estimate Revision • Aug 02Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$286.5m to US$282.9m. Losses expected to increase from US$0.75 per share to US$0.96. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target broadly unchanged at US$151. Share price rose 5.1% to US$90.55 over the past week.Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.97 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$64.8m (up 7.1% from 1Q 2021). Net loss: US$9.99m (down US$11.9m from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 471%. Over the next year, revenue is forecast to grow 15%, compared to a 9.0% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.분석 기사 • May 09Is Heska (NASDAQ:HSKA) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Price Target Changed • Apr 27Price target decreased to US$195Down from US$219, the current price target is an average from 6 analysts. New target price is 62% above last closing price of US$121. Stock is down 34% over the past year. The company is forecast to post earnings per share of US$0.19 next year compared to a net loss per share of US$0.11 last year.분석 기사 • Apr 03Heska Corporation (NASDAQ:HSKA) Shares Could Be 50% Below Their Intrinsic Value EstimateDoes the April share price for Heska Corporation ( NASDAQ:HSKA ) reflect what it's really worth? Today, we will...Recent Insider Transactions Derivative • Mar 13Executive VP & CFO exercised options and sold US$81k worth of stockOn the 7th of March, Catherine Grassman exercised options to acquire 545 shares at no cost and sold these for an average price of US$149 per share. This trade did not impact their existing holding. Since June 2021, Catherine's direct individual holding has increased from 3.97k shares to 9.54k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Mar 04Executive VP recently sold US$97k worth of stockOn the 3rd of March, Eleanor Baker sold around 663 shares on-market at roughly US$146 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.0m more than they bought in the last 12 months.Price Target Changed • Mar 03Price target decreased to US$199Down from US$229, the current price target is an average from 6 analysts. New target price is 36% above last closing price of US$146. Stock is down 19% over the past year. The company is forecast to post earnings per share of US$0.20 next year compared to a net loss per share of US$0.11 last year.분석 기사 • Mar 02What Is Heska Corporation's (NASDAQ:HSKA) Share Price Doing?Heska Corporation ( NASDAQ:HSKA ), might not be a large cap stock, but it saw a double-digit share price rise of over...Reported Earnings • Mar 02Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.12 loss per share (up from US$1.66 loss in FY 2020). Revenue: US$253.7m (up 29% from FY 2020). Net loss: US$1.15m (loss narrowed 92% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.Price Target Changed • Mar 01Price target decreased to US$219Down from US$253, the current price target is an average from 4 analysts. New target price is 54% above last closing price of US$142. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.10 next year compared to a net loss per share of US$1.66 last year.Recent Insider Transactions Derivative • Feb 24Director exercised options to buy US$1.1m worth of stock.On the 17th of February, David Sveen exercised options to buy 9k shares at a strike price of around US$33.06, costing a total of US$283k. This transaction amounted to 26% of their direct individual holding at the time of the trade. Since March 2021, David's direct individual holding has increased from 30.69k shares to 32.74k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Feb 18CEO, President & Director exercised options to buy US$5.7m worth of stock.On the 11th of February, Kevin Wilson exercised options to buy 45k shares at a strike price of around US$20.25, costing a total of US$914k. This transaction amounted to 19% of their direct individual holding at the time of the trade. Since March 2021, Kevin's direct individual holding has increased from 233.57k shares to 280.72k. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Feb 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.09 to -US$0.10 per share. Revenue forecast of US$251.5m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$253 unchanged from last update. Share price fell 3.9% to US$133 over the past week.Buying Opportunity • Jan 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 42%. The fair value is estimated to be US$163, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% per annum over the last 3 years. The company has become profitable over the last year.Major Estimate Revision • Jan 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.05 to -US$0.09 per share. Revenue forecast unchanged at US$251.6m. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$239 unchanged from last update. Share price fell 3.7% to US$138 over the past week.분석 기사 • Jan 09Heska (NASDAQ:HSKA) Has A Rock Solid Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • Dec 13Estimating The Fair Value Of Heska Corporation (NASDAQ:HSKA)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Heska Corporation...Recent Insider Transactions • Nov 29CEO, President & Director recently bought US$173k worth of stockOn the 23rd of November, Kevin Wilson bought around 1k shares on-market at roughly US$173 per share. In the last 3 months, they made an even bigger purchase worth US$179k. Kevin has been a buyer over the last 12 months, purchasing a net total of US$352k worth in shares.Recent Insider Transactions • Nov 19CEO, President & Director recently bought US$179k worth of stockOn the 15th of November, Kevin Wilson bought around 1k shares on-market at roughly US$179 per share. This was the largest purchase by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.Price Target Changed • Nov 19Price target decreased to US$246Down from US$283, the current price target is an average from 4 analysts. New target price is 37% above last closing price of US$179. Stock is up 45% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$1.66 last year.분석 기사 • Nov 17What Does Heska Corporation's (NASDAQ:HSKA) Share Price Indicate?While Heska Corporation ( NASDAQ:HSKA ) might not be the most widely known stock at the moment, it saw significant...Recent Insider Transactions Derivative • Nov 06Executive VP & COO exercised options to buy US$1.9m worth of stock.On the 2nd of November, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$6.90, costing a total of US$69k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since December 2020, Nancy's direct individual holding has increased from 51.87k shares to 54.52k. Company insiders have collectively sold US$4.8m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Nov 05Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$60.2m (up 6.4% from 3Q 2020). Net loss: US$1.90m (loss narrowed 64% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.분석 기사 • Sep 28Is Heska (NASDAQ:HSKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Recent Insider Transactions Derivative • Aug 29CEO, President & Director notifies of intention to sell stockKevin Wilson intends to sell 44k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$272, it would amount to US$12m. For the year to December 2020, Kevin's total compensation was 35% salary and 65% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2020, Kevin's direct individual holding has increased from 229.61k shares to 233.57k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions Derivative • Aug 20Independent Director exercised options and sold US$477k worth of stockOn the 17th of August, Sharon Larson exercised 2k options at a strike price of around US$28.41 and sold these shares for an average price of US$267 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Aug 20Executive VP & COO recently sold US$270k worth of stockOn the 18th of August, Nancy Wisnewski sold around 1k shares on-market at roughly US$270 per share. In the last 3 months, they made an even bigger sale worth US$989k. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.7m.Recent Insider Transactions Derivative • Aug 11Executive VP & CFO exercised options and sold US$952k worth of stockOn the 6th of August, Catherine Grassman exercised 5k options at a strike price of around US$69.77 and sold these shares for an average price of US$260 per share. This trade did not impact their existing holding. Since March 2021, Catherine's direct individual holding has decreased from 4.24k shares to 3.97k. Company insiders have collectively sold US$4.2m more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Aug 04Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.72 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$64.9m (up 42% from 2Q 2020). Net loss: US$567.0k (loss narrowed 91% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.분석 기사 • Jul 21Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?Heska Corporation ( NASDAQ:HSKA ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...분석 기사 • Jun 29Is Heska (NASDAQ:HSKA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Recent Insider Transactions • Jun 08Executive VP & COO recently sold US$989k worth of stockOn the 4th of June, Nancy Wisnewski sold around 5k shares on-market at roughly US$198 per share. This was the largest sale by an insider in the last 3 months. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.4m.분석 기사 • May 28Calculating The Intrinsic Value Of Heska Corporation (NASDAQ:HSKA)In this article we are going to estimate the intrinsic value of Heska Corporation ( NASDAQ:HSKA ) by taking the...Recent Insider Transactions Derivative • May 26Independent Director exercised options and sold US$530k worth of stockOn the 24th of May, Sharon Larson exercised 3k options at a strike price of around US$28.41 and sold these shares for an average price of US$205 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.4m more than they bought, via options and on-market transactions in the last 12 months.Executive Departure • May 12Independent Director has left the companyOn the 5th of May, Bonnie Trowbridge's tenure as Independent Director ended after 6.3 years in the role. As of December 2020, Bonnie personally held 4.09k shares (US$596k worth at the time). Bonnie is the only executive to leave the company over the last 12 months.Price Target Changed • May 12Price target increased to US$221Up from US$205, the current price target is an average from 6 analysts. New target price is 15% above last closing price of US$191. Stock is up 146% over the past year.Major Estimate Revision • May 08Consensus EPS estimates increase to US$0.54The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$232.9m to US$247.3m. Forecast to become profitable, with EPS estimate increasing from -US$0.48 to US$0.54. Medical Equipment industry in the US expected to see average net income growth of 28% next year. Consensus price target up from US$205 to US$213. Share price rose 9.5% to US$200 over the past week.Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.20 (vs US$0.70 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$60.5m (up 97% from 1Q 2020). Net income: US$1.87m (up US$7.16m from 1Q 2020). Profit margin: 3.1% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 137 percentage points per year, which is a significant difference in performance.Recent Insider Transactions Derivative • May 04Executive VP & COO exercised options to buy US$1.4m worth of stock.On the 30th of April, Nancy Wisnewski exercised options to buy 8k shares at a strike price of around US$6.76, costing a total of US$51k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.44k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.분석 기사 • Apr 15Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?While Heska Corporation ( NASDAQ:HSKA ) might not be the most widely known stock at the moment, it saw a significant...분석 기사 • Mar 19How Much Are Heska Corporation (NASDAQ:HSKA) Insiders Taking Off The Table?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...Recent Insider Transactions Derivative • Mar 12Executive VP & COO exercised options and sold US$78k worth of stockOn the 7th of March, Nancy Wisnewski exercised options to acquire 452 shares at no cost and sold these for an average price of US$172 per share. This trade did not impact their existing holding. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.87k. Company insiders have collectively sold US$5.1m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Mar 08Analysts update estimatesThe 2021 consensus revenue estimate increased from US$227.3m to US$229.9m. The company's losses in 2021 are expected to worsen with analysts lowering their EPS forecasts from -US$0.34 to -US$0.48. The Medical Equipment industry in the US is expected to see an average net income growth of 20% next year. The consensus price target of US$209 was unchanged from the last update. Share price is down by 8.9% to US$172 over the past week.Is New 90 Day High Low • Feb 25New 90-day high: US$207The company is up 64% from its price of US$126 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$77.45 per share.Reported Earnings • Feb 24Full year 2020 earnings released: US$1.52 loss per share (vs US$0.20 loss in FY 2019)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$197.3m (up 61% from FY 2019). Net loss: US$14.4m (loss widened US$12.9m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.Analyst Estimate Surprise Post Earnings • Feb 24Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the Medical Equipment industry in the US.분석 기사 • Feb 21A Look At The Fair Value Of Heska Corporation (NASDAQ:HSKA)Today we will run through one way of estimating the intrinsic value of Heska Corporation ( NASDAQ:HSKA ) by estimating...Is New 90 Day High Low • Feb 02New 90-day high: US$181The company is up 55% from its price of US$116 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$192 per share.매출 및 비용 세부 내역Heska가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:HSKA 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 23255-201132031 Dec 22257-201122030 Sep 22259-16100930 Jun 22258-18105931 Mar 22258-13104831 Dec 21254-1100730 Sep 21250292830 Jun 21246-193831 Mar 21227-785831 Dec 20197-1474930 Sep 20167-1970830 Jun 20141-1453831 Mar 20124-846931 Dec 19123-145830 Sep 19123437730 Jun 19123243631 Mar 19124543431 Dec 18127650330 Sep 18129148330 Jun 18129639231 Mar 18133839231 Dec 171291038230 Sep 171331438230 Jun 171361538231 Mar 171321436231 Dec 161301135230 Sep 16120935230 Jun 16115734231 Mar 16109633231 Dec 15105534230 Sep 1599433230 Jun 1593332131 Mar 1592332131 Dec 1490331130 Sep 1489331130 Jun 1485330131 Mar 1480-130131 Dec 1378-131230 Sep 1373-230130 Jun 1373-229131 Mar 1373029131 Dec 1273128130 Sep 1270127130 Jun 12712271양질의 수익: HSKA 은(는) 현재 수익성이 없습니다.이익 마진 증가: HSKA는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: HSKA은 수익성이 없으며 지난 5년 동안 손실이 연평균 55.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 HSKA의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: HSKA은 수익성이 없어 지난 해 수익 성장률을 Medical Equipment 업계(14.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: HSKA는 현재 수익성이 없으므로 자본 수익률이 음수(-4.8%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YHealthcare 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/14 23:56종가2023/06/12 00:00수익2023/03/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Heska Corporation는 11명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Benjamin HaynorAlliance Global PartnersRaymond MyersBenchmark CompanyKara AndersonB. Riley Securities, Inc.8명의 분석가 더 보기
Reported Earnings • May 06First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.97 loss per share (further deteriorated from US$0.97 loss in 1Q 2022). Revenue: US$62.4m (down 3.7% from 1Q 2022). Net loss: US$10.1m (loss widened 1.4% from 1Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Reported Earnings • Mar 01Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1,923 loss per share (further deteriorated from US$0.12 loss in FY 2021). Revenue: US$257.3m (up 1.4% from FY 2021). Net loss: US$19.9m (loss widened US$18.7m from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.
공시 • Feb 09Heska Corporation to Report Q4, 2022 Results on Feb 28, 2023Heska Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 28, 2023
Reported Earnings • Nov 09Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.042 loss per share (improved from US$0.19 loss in 3Q 2021). Revenue: US$61.5m (up 2.1% from 3Q 2021). Net loss: US$436.0k (loss narrowed 77% from 3Q 2021). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Reported Earnings • Aug 08Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.51 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$64.7m (flat on 2Q 2021). Net loss: US$5.25m (loss widened US$4.68m from 2Q 2021). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 374%. Over the next year, revenue is forecast to grow 16%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.97 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$64.8m (up 7.1% from 1Q 2021). Net loss: US$9.99m (down US$11.9m from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 471%. Over the next year, revenue is forecast to grow 15%, compared to a 9.0% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
공시 • Jun 15Heska Corporation(NasdaqCM:HSKA) dropped from NASDAQ Composite IndexHeska Corporation removed
공시 • Jun 14Heska Corporation Announces Board ChangesHeska Corporation announced that pursuant to the Merger Agreement, at the Effective Time, all of the members of the company's board of directors (which consisted of Sharon J. Maples, David E. Sveen, Ph.D., Stephen L. Davis, Robert L. Antin, Mark F. Furlong, Dr. Joachim Hasenmaier, Scott W. Humphrey and Kevin S. Wilson) ceased to be directors of the company, and Nefertiti Greene, Giamabatista Martano and Timothy Hirsch became directors of the company. Also in connection with the Merger and as contemplated by the Merger Agreement, following the consummation of the Merger, Nefertiti Greene, Giambatista Martano, Timothy Hirsch, Keith Melman, Anthony Gedeller, Peter Kim and Chad Susie became officers of the company.
Reported Earnings • May 06First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: US$0.97 loss per share (further deteriorated from US$0.97 loss in 1Q 2022). Revenue: US$62.4m (down 3.7% from 1Q 2022). Net loss: US$10.1m (loss widened 1.4% from 1Q 2022). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 80%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Price Target Changed • Apr 04Price target increased by 22% to US$130Up from US$106, the current price target is an average from 4 analysts. New target price is 11% above last closing price of US$117. Stock is down 19% over the past year. The company is forecast to post a net loss per share of US$0.85 next year compared to a net loss per share of US$1.92 last year.
Reported Earnings • Mar 01Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$1,923 loss per share (further deteriorated from US$0.12 loss in FY 2021). Revenue: US$257.3m (up 1.4% from FY 2021). Net loss: US$19.9m (loss widened US$18.7m from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 21%. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.
공시 • Feb 09Heska Corporation to Report Q4, 2022 Results on Feb 28, 2023Heska Corporation announced that they will report Q4, 2022 results at 9:30 AM, US Eastern Standard Time on Feb 28, 2023
분석 기사 • Feb 09Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?Heska Corporation ( NASDAQ:HSKA ), is not the largest company out there, but it saw a significant share price rise of...
공시 • Feb 02Heska Corporation Announces Nancy Wisnewski Step Downs as Executive Vice President and Chief Operating Officer, Effective March 31, 2023On January 27, 2023, Nancy Wisnewski, Ph.D., Executive Vice President, Chief Operating Officer of Heska Corporation (the “Company”), informed the Company that after more than 30 years of service, she will step down from such position effective March 31, 2023. Dr. Wisnewski will remain with the Company in the position of Chief Science Advisor to the CEO. The Company expects to prepare operational team leadership changes in advance of the transition that begins March 31, 2023.
분석 기사 • Jan 18Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 50%?How far off is Heska Corporation ( NASDAQ:HSKA ) from its intrinsic value? Using the most recent financial data, we'll...
공시 • Jan 04Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc.Heska Corporation (NasdaqCM:HSKA) entered a definitive agreement to acquire MBio Diagnostics, Inc. for $38.7 million on September 9, 2022. The consideration includes a mix of cash and debt forgiveness, subject to working capital and other adjustments. The transaction is expected to close in the first half of 2023, subject to customary closing conditions. As per the filling on November 8, 2022, both companies board of directors approved the merger. Heska Corporation (NasdaqCM:HSKA) acquired MBio Diagnostics, Inc. on January 3, 2023.
Price Target Changed • Nov 16Price target decreased to US$123Down from US$142, the current price target is an average from 5 analysts. New target price is 73% above last closing price of US$70.92. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.59 next year compared to a net loss per share of US$0.11 last year.
Reported Earnings • Nov 09Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: US$0.042 loss per share (improved from US$0.19 loss in 3Q 2021). Revenue: US$61.5m (up 2.1% from 3Q 2021). Net loss: US$436.0k (loss narrowed 77% from 3Q 2021). Revenue missed analyst estimates by 9.7%. Earnings per share (EPS) exceeded analyst estimates by 48%. Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Seeking Alpha • Sep 12Heska to acquire LightDeck Diagnostics for $38.7MHeska (NASDAQ:HSKA) to acquire 100% of the share capital of MBio Diagnostics, d/b/a LightDeck Diagnostics, an innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Heska will purchase LightDeck for a purchase price of $38.7 million. Transaction is expected to close in H1 2023.
Recent Insider Transactions Derivative • Sep 07Executive VP & COO exercised options to buy US$880k worth of stock.On the 1st of September, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$8.55, costing a total of US$86k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2021, Nancy's direct individual holding has increased from 54.52k shares to 71.03k. Company insiders have collectively bought US$1.5m more than they sold, via options and on-market transactions, in the last 12 months.
분석 기사 • Sep 07Is Heska (NASDAQ:HSKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Major Estimate Revision • Aug 18Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$1.31 to -US$1.45 per share. Revenue forecast unchanged at US$273.3m. Medical Equipment industry in the US expected to see average net income growth of 11% next year. Consensus price target broadly unchanged at US$147. Share price rose 5.4% to US$95.69 over the past week.
분석 기사 • Aug 17Are Investors Undervaluing Heska Corporation (NASDAQ:HSKA) By 31%?How far off is Heska Corporation ( NASDAQ:HSKA ) from its intrinsic value? Using the most recent financial data, we'll...
Reported Earnings • Aug 08Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.51 loss per share (down from US$0.056 loss in 2Q 2021). Revenue: US$64.7m (flat on 2Q 2021). Net loss: US$5.25m (loss widened US$4.68m from 2Q 2021). Revenue missed analyst estimates by 5.5%. Earnings per share (EPS) also missed analyst estimates by 374%. Over the next year, revenue is forecast to grow 16%, compared to a 6.5% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
Seeking Alpha • Aug 08Heska Non-GAAP EPS of $0.34 misses by $0.03, revenue of $64.7M misses by $3.76MHeska press release (NASDAQ:HSKA): Q2 Non-GAAP EPS of $0.34 misses by $0.03. Revenue of $64.7M (-0.4% Y/Y) misses by $3.76M. Consolidated gross margin improved approximately 30 bps to 42.3%. Consolidated operating margin declined from negative 1.1% to negative 8.6%.
Major Estimate Revision • Aug 02Consensus EPS estimates fall by 28%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$286.5m to US$282.9m. Losses expected to increase from US$0.75 per share to US$0.96. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target broadly unchanged at US$151. Share price rose 5.1% to US$90.55 over the past week.
Reported Earnings • May 10First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.97 loss per share (down from US$0.20 profit in 1Q 2021). Revenue: US$64.8m (up 7.1% from 1Q 2021). Net loss: US$9.99m (down US$11.9m from profit in 1Q 2021). Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 471%. Over the next year, revenue is forecast to grow 15%, compared to a 9.0% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
분석 기사 • May 09Is Heska (NASDAQ:HSKA) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Price Target Changed • Apr 27Price target decreased to US$195Down from US$219, the current price target is an average from 6 analysts. New target price is 62% above last closing price of US$121. Stock is down 34% over the past year. The company is forecast to post earnings per share of US$0.19 next year compared to a net loss per share of US$0.11 last year.
분석 기사 • Apr 03Heska Corporation (NASDAQ:HSKA) Shares Could Be 50% Below Their Intrinsic Value EstimateDoes the April share price for Heska Corporation ( NASDAQ:HSKA ) reflect what it's really worth? Today, we will...
Recent Insider Transactions Derivative • Mar 13Executive VP & CFO exercised options and sold US$81k worth of stockOn the 7th of March, Catherine Grassman exercised options to acquire 545 shares at no cost and sold these for an average price of US$149 per share. This trade did not impact their existing holding. Since June 2021, Catherine's direct individual holding has increased from 3.97k shares to 9.54k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Mar 04Executive VP recently sold US$97k worth of stockOn the 3rd of March, Eleanor Baker sold around 663 shares on-market at roughly US$146 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$1.0m more than they bought in the last 12 months.
Price Target Changed • Mar 03Price target decreased to US$199Down from US$229, the current price target is an average from 6 analysts. New target price is 36% above last closing price of US$146. Stock is down 19% over the past year. The company is forecast to post earnings per share of US$0.20 next year compared to a net loss per share of US$0.11 last year.
분석 기사 • Mar 02What Is Heska Corporation's (NASDAQ:HSKA) Share Price Doing?Heska Corporation ( NASDAQ:HSKA ), might not be a large cap stock, but it saw a double-digit share price rise of over...
Reported Earnings • Mar 02Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: US$0.12 loss per share (up from US$1.66 loss in FY 2020). Revenue: US$253.7m (up 29% from FY 2020). Net loss: US$1.15m (loss narrowed 92% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 4.8%. Over the next year, revenue is forecast to grow 13%, compared to a 11% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings.
Price Target Changed • Mar 01Price target decreased to US$219Down from US$253, the current price target is an average from 4 analysts. New target price is 54% above last closing price of US$142. Stock is down 29% over the past year. The company is forecast to post a net loss per share of US$0.10 next year compared to a net loss per share of US$1.66 last year.
Recent Insider Transactions Derivative • Feb 24Director exercised options to buy US$1.1m worth of stock.On the 17th of February, David Sveen exercised options to buy 9k shares at a strike price of around US$33.06, costing a total of US$283k. This transaction amounted to 26% of their direct individual holding at the time of the trade. Since March 2021, David's direct individual holding has increased from 30.69k shares to 32.74k. Company insiders have collectively sold US$1.7m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Feb 18CEO, President & Director exercised options to buy US$5.7m worth of stock.On the 11th of February, Kevin Wilson exercised options to buy 45k shares at a strike price of around US$20.25, costing a total of US$914k. This transaction amounted to 19% of their direct individual holding at the time of the trade. Since March 2021, Kevin's direct individual holding has increased from 233.57k shares to 280.72k. Company insiders have collectively sold US$2.0m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Feb 09Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.09 to -US$0.10 per share. Revenue forecast of US$251.5m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 16% next year. Consensus price target of US$253 unchanged from last update. Share price fell 3.9% to US$133 over the past week.
Buying Opportunity • Jan 28Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 42%. The fair value is estimated to be US$163, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 28% per annum over the last 3 years. The company has become profitable over the last year.
Major Estimate Revision • Jan 27Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.05 to -US$0.09 per share. Revenue forecast unchanged at US$251.6m. Medical Equipment industry in the US expected to see average net income growth of 17% next year. Consensus price target of US$239 unchanged from last update. Share price fell 3.7% to US$138 over the past week.
분석 기사 • Jan 09Heska (NASDAQ:HSKA) Has A Rock Solid Balance SheetSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • Dec 13Estimating The Fair Value Of Heska Corporation (NASDAQ:HSKA)Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Heska Corporation...
Recent Insider Transactions • Nov 29CEO, President & Director recently bought US$173k worth of stockOn the 23rd of November, Kevin Wilson bought around 1k shares on-market at roughly US$173 per share. In the last 3 months, they made an even bigger purchase worth US$179k. Kevin has been a buyer over the last 12 months, purchasing a net total of US$352k worth in shares.
Recent Insider Transactions • Nov 19CEO, President & Director recently bought US$179k worth of stockOn the 15th of November, Kevin Wilson bought around 1k shares on-market at roughly US$179 per share. This was the largest purchase by an insider in the last 3 months. This was Kevin's only on-market trade for the last 12 months.
Price Target Changed • Nov 19Price target decreased to US$246Down from US$283, the current price target is an average from 4 analysts. New target price is 37% above last closing price of US$179. Stock is up 45% over the past year. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$1.66 last year.
분석 기사 • Nov 17What Does Heska Corporation's (NASDAQ:HSKA) Share Price Indicate?While Heska Corporation ( NASDAQ:HSKA ) might not be the most widely known stock at the moment, it saw significant...
Recent Insider Transactions Derivative • Nov 06Executive VP & COO exercised options to buy US$1.9m worth of stock.On the 2nd of November, Nancy Wisnewski exercised options to buy 10k shares at a strike price of around US$6.90, costing a total of US$69k. This transaction amounted to 18% of their direct individual holding at the time of the trade. Since December 2020, Nancy's direct individual holding has increased from 51.87k shares to 54.52k. Company insiders have collectively sold US$4.8m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Nov 05Third quarter 2021 earnings releasedThe company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: US$60.2m (up 6.4% from 3Q 2020). Net loss: US$1.90m (loss narrowed 64% from 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 112 percentage points per year, which is a significant difference in performance.
분석 기사 • Sep 28Is Heska (NASDAQ:HSKA) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Recent Insider Transactions Derivative • Aug 29CEO, President & Director notifies of intention to sell stockKevin Wilson intends to sell 44k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$272, it would amount to US$12m. For the year to December 2020, Kevin's total compensation was 35% salary and 65% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since December 2020, Kevin's direct individual holding has increased from 229.61k shares to 233.57k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Aug 20Independent Director exercised options and sold US$477k worth of stockOn the 17th of August, Sharon Larson exercised 2k options at a strike price of around US$28.41 and sold these shares for an average price of US$267 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Aug 20Executive VP & COO recently sold US$270k worth of stockOn the 18th of August, Nancy Wisnewski sold around 1k shares on-market at roughly US$270 per share. In the last 3 months, they made an even bigger sale worth US$989k. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.7m.
Recent Insider Transactions Derivative • Aug 11Executive VP & CFO exercised options and sold US$952k worth of stockOn the 6th of August, Catherine Grassman exercised 5k options at a strike price of around US$69.77 and sold these shares for an average price of US$260 per share. This trade did not impact their existing holding. Since March 2021, Catherine's direct individual holding has decreased from 4.24k shares to 3.97k. Company insiders have collectively sold US$4.2m more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Aug 04Second quarter 2021 earnings released: US$0.056 loss per share (vs US$0.72 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$64.9m (up 42% from 2Q 2020). Net loss: US$567.0k (loss narrowed 91% from 2Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 127 percentage points per year, which is a significant difference in performance.
분석 기사 • Jul 21Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?Heska Corporation ( NASDAQ:HSKA ), might not be a large cap stock, but it led the NASDAQCM gainers with a relatively...
분석 기사 • Jun 29Is Heska (NASDAQ:HSKA) A Risky Investment?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Recent Insider Transactions • Jun 08Executive VP & COO recently sold US$989k worth of stockOn the 4th of June, Nancy Wisnewski sold around 5k shares on-market at roughly US$198 per share. This was the largest sale by an insider in the last 3 months. Nancy has been a seller over the last 12 months, reducing personal holdings by US$1.4m.
분석 기사 • May 28Calculating The Intrinsic Value Of Heska Corporation (NASDAQ:HSKA)In this article we are going to estimate the intrinsic value of Heska Corporation ( NASDAQ:HSKA ) by taking the...
Recent Insider Transactions Derivative • May 26Independent Director exercised options and sold US$530k worth of stockOn the 24th of May, Sharon Larson exercised 3k options at a strike price of around US$28.41 and sold these shares for an average price of US$205 per share. This trade did not impact their existing holding. Since March 2021, Sharon's direct individual holding has increased from 4.79k shares to 7.50k. Company insiders have collectively sold US$5.4m more than they bought, via options and on-market transactions in the last 12 months.
Executive Departure • May 12Independent Director has left the companyOn the 5th of May, Bonnie Trowbridge's tenure as Independent Director ended after 6.3 years in the role. As of December 2020, Bonnie personally held 4.09k shares (US$596k worth at the time). Bonnie is the only executive to leave the company over the last 12 months.
Price Target Changed • May 12Price target increased to US$221Up from US$205, the current price target is an average from 6 analysts. New target price is 15% above last closing price of US$191. Stock is up 146% over the past year.
Major Estimate Revision • May 08Consensus EPS estimates increase to US$0.54The consensus outlook for earnings per share (EPS) in 2021 has improved. 2021 revenue forecast increased from US$232.9m to US$247.3m. Forecast to become profitable, with EPS estimate increasing from -US$0.48 to US$0.54. Medical Equipment industry in the US expected to see average net income growth of 28% next year. Consensus price target up from US$205 to US$213. Share price rose 9.5% to US$200 over the past week.
Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.20 (vs US$0.70 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$60.5m (up 97% from 1Q 2020). Net income: US$1.87m (up US$7.16m from 1Q 2020). Profit margin: 3.1% (up from net loss in 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 137 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions Derivative • May 04Executive VP & COO exercised options to buy US$1.4m worth of stock.On the 30th of April, Nancy Wisnewski exercised options to buy 8k shares at a strike price of around US$6.76, costing a total of US$51k. This transaction amounted to 14% of their direct individual holding at the time of the trade. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.44k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months.
분석 기사 • Apr 15Is Heska Corporation (NASDAQ:HSKA) Potentially Undervalued?While Heska Corporation ( NASDAQ:HSKA ) might not be the most widely known stock at the moment, it saw a significant...
분석 기사 • Mar 19How Much Are Heska Corporation (NASDAQ:HSKA) Insiders Taking Off The Table?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
Recent Insider Transactions Derivative • Mar 12Executive VP & COO exercised options and sold US$78k worth of stockOn the 7th of March, Nancy Wisnewski exercised options to acquire 452 shares at no cost and sold these for an average price of US$172 per share. This trade did not impact their existing holding. Since September 2020, Nancy's direct individual holding has increased from 48.37k shares to 51.87k. Company insiders have collectively sold US$5.1m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Mar 08Analysts update estimatesThe 2021 consensus revenue estimate increased from US$227.3m to US$229.9m. The company's losses in 2021 are expected to worsen with analysts lowering their EPS forecasts from -US$0.34 to -US$0.48. The Medical Equipment industry in the US is expected to see an average net income growth of 20% next year. The consensus price target of US$209 was unchanged from the last update. Share price is down by 8.9% to US$172 over the past week.
Is New 90 Day High Low • Feb 25New 90-day high: US$207The company is up 64% from its price of US$126 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$77.45 per share.
Reported Earnings • Feb 24Full year 2020 earnings released: US$1.52 loss per share (vs US$0.20 loss in FY 2019)The company reported a mediocre full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: US$197.3m (up 61% from FY 2019). Net loss: US$14.4m (loss widened US$12.9m from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 164 percentage points per year, which is a significant difference in performance.
Analyst Estimate Surprise Post Earnings • Feb 24Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 6.1%. Earnings per share (EPS) missed analyst estimates by 25%. Over the next year, revenue is forecast to grow 13%, compared to a 20% growth forecast for the Medical Equipment industry in the US.
분석 기사 • Feb 21A Look At The Fair Value Of Heska Corporation (NASDAQ:HSKA)Today we will run through one way of estimating the intrinsic value of Heska Corporation ( NASDAQ:HSKA ) by estimating...
Is New 90 Day High Low • Feb 02New 90-day high: US$181The company is up 55% from its price of US$116 on 03 November 2020. The American market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$192 per share.